Vinod Gidvani-Diaz
Pediatric Hematology-Oncology · San Antonio, TXNPI 1568492387
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $85,412 of the $100,717 with a category attached, or 84.8%. Jazz Pharmaceuticals Inc. accounts for 97.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $37,864 and has fallen 72.6% since, to $10,380 in 2025. Among pediatric hematology-oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $875.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$98K
- Foundation Medicine, Inc.$700
- Sobi, Inc$381
- AstraZeneca$267
- Servier Pharmaceuticals LLC$261
- Genentech USA, Inc.$207
- plus $673 from 8 others
Across 9 payments — averaging $36,698 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$330K
- Novartis$393
What the payments were for
- Consulting fees$2,2902%
- Speaking & faculty fees$85,41285%
- Travel & lodging$8,7289%
- Food & beverage$4,2864%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 81 | $98,228 |
| Foundation Medicine, Inc. | 2 | $700 |
| Sobi, Inc | 4 | $381 |
| AstraZeneca(2 entities) | 5 | $267 |
| Servier Pharmaceuticals LLC | 3 | $261 |
| Genentech USA, Inc. | 3 | $207 |
| Amgen(2 entities) | 2 | $141 |
| Incyte Corporation | 1 | $130 |
| RARE Disease Therapeutics, Inc. | 1 | $115 |
| Novartis | 7 | $107 |
| BTG International Inc. | 2 | $95 |
| United Therapeutics Corporation | 1 | $31 |
| Cumberland Pharmaceuticals, Inc. | 2 | $27 |
| Nestle Healthcare Nutrition Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYLAZE$96,958
- FOUNDATIONONE LIQUID$700
- FOUNDATIONFOCUS$700
- FOUNDATIONONE CDX$700
- FOUNDATIONONE HEME$700
- FOUNDATIONONE$700
- DEFITELIO$356
- Gamifant$253
- HEMLIBRA$137
- JAKAFI$130
- ACTIMMUNE$125
- ONCASPAR$122
- Purixan$115
How this compares
$100,717 in reported general payments places this provider in the 95th percentile of 235 pediatric hematology-oncology providers in Texas.
Other pediatric hematology-oncology in San Antonio
- Scott PenneySan Antonio$75K
- Chatchawin AssanasenSan Antonio$65K
- Samuel Pabon RiveraSan Antonio$23K
- Allison GrimesSan Antonio$21K
- Aaron SugalskiSan Antonio$9K
- Ghadir SasaSan Antonio$5K
- Lorimar RamirezSan Antonio$4K
- Mark GarciaSan Antonio$3K
- Anne-Marie LangevinSan Antonio$3K
- Amanda LipsittSan Antonio$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.